市場調査レポート

商品コード

1298247

神経変性薬市場：薬剤クラス別、適応症別、流通チャネル別：2021-2031年の世界機会分析と産業予測

Neurodegenerative Drugs Market By Drug Class, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: 2023年03月01日 | 発行: Allied Market Research

| ページ情報: 英文 300 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,570 560,989円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,730 900,412円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,508,544円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

神経変性薬市場は、2021年には362億7,720万米ドルと評価され、2031年には748億938万米ドルに達すると推定され、2022年から2031年までのCAGRは7.5%です。

神経変性疾患とは、主に脳や脊髄のニューロン（神経細胞）に影響を及ぼし、徐々に変性していく疾患群を指します。これらの疾患は通常、進行性で慢性的であり、時間とともに症状が悪化します。神経変性疾患の例としては、アルツハイマー病、パーキンソン病、ハンチントン病、筋萎縮性側索硬化症（ALS）、多発性硬化症（MS）などがあります。これらの疾患は、人の認知機能、運動機能、感覚機能に大きな影響を及ぼし、最終的には身体障害や死に至ることもあります。

神経変性疾患の治療に使用される薬剤は、疾患の進行を遅らせたり、症状を緩和したりするためのものです。使用される具体的な薬剤は、治療対象となる神経変性疾患の種類によって異なります。例えば、アルツハイマー病の治療に用いられる薬剤にはコリンエステラーゼ阻害剤やメマンチンなどがあり、パーキンソン病の治療に用いられる薬剤にはレボドパ、ドーパミン作動薬、MAO-B阻害剤などがあります。

世界の神経変性薬市場の成長を促す主な要因は、神経変性疾患に伴う症状をコントロールするための先進的な薬剤に対する需要の増加です。さらに、神経変性疾患に対する強力なパイプラインが市場の主要動向であり、これが市場の成長を促進すると予想されます。患者数の大幅な増加が薬剤の需要増につながっています。しかし、医薬品開発プロセスに伴う合併症や医薬品の副作用が市場成長の妨げになると予想されます。

一方、未開拓の新興国における高い成長ポテンシャル、多発性硬化症治療薬BAF312やオレラブルチニブのようなパイプライン製品の増加、神経変性疾患の継続的な医薬品承認は、市場プレイヤーに有利な機会を提供すると予想されます。例えば、2020年1月、ノバルティスAGは、欧州委員会（EC）が、再発または炎症活動の画像的特徴によって証明される活動性の二次性進行性多発性硬化症（SPMS）の成人患者の治療薬としてメイゼント（シポニモド）を承認したと発表しました。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
- 供給企業の交渉力
- 買い手の交渉力
- 代替品の脅威
- 新規参入業者の脅威
- 競合の激しさ
市場力学
- 促進要因
  - 神経変性疾患の増加
  - 政府および非政府組織別取り組み
  - 予測期間中の新薬上市の見込み
- 阻害要因
  - 医薬品開発に伴う合併症
- 機会
  - 研究開発活動の増加
COVID-19市場への影響分析

第4章神経変性薬市場：薬剤クラス別

概要
- 市場規模および予測
ドーパミン作動薬
- 主要市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
脱炭酸酵素阻害薬
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
コリンエステラーゼ阻害剤
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
免疫調節薬
- 主要市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別

第5章神経変性薬市場：適応症別

概要
- 市場規模および予測
パーキンソン病
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
アルツハイマー病
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
多発性硬化症
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
その他
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別

第6章神経変性薬市場：流通チャネル別

概要
- 市場規模および予測
病院薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
オンラインプロバイダー
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
ドラッグストアと小売薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別

第7章神経変性薬市場：地域別

概要
- 市場規模・予測：地域別
北米
- 主要動向と機会
- 市場規模・予測：薬剤クラス別
- 市場規模・予測：適応症別
- 市場規模・予測：流通チャネル別
- 市場規模・予測：国別
  - 米国
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - カナダ
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - メキシコ
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
欧州
- 主要動向と機会
- 市場規模・予測：薬剤クラス別
- 市場規模・予測：適応症別
- 市場規模・予測：流通チャネル別
- 市場規模・予測：国別
  - ドイツ
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - フランス
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - 英国
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - イタリア
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - スペイン
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - その他欧州
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
アジア太平洋地域
- 主要動向と機会
- 市場規模・予測：薬剤クラス別
- 市場規模・予測：適応症別
- 市場規模・予測：流通チャネル別
- 市場規模・予測：国別
  - 日本
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - 中国
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - オーストラリア
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - インド
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - 韓国
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - その他アジア太平洋地域
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
ラテンアメリカ・中東・アフリカ
- 主要動向と機会
- 市場規模・予測：薬剤クラス別
- 市場規模・予測：適応症別
- 市場規模・予測：流通チャネル別
- 市場規模・予測：国別
  - ブラジル
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - サウジアラビア
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - 南アフリカ
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別
  - その他の地域
  - 主要市場動向、成長要因、機会
  - 市場規模・予測：薬剤クラス別
  - 市場規模・予測：適応症別
  - 市場規模・予測：流通チャネル別

第8章競合情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
トップ企業のポジショニング（2021年）

第9章企業プロファイル

Novartis AG
AbbVie Inc.
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Sanofi
Orion Corporation
Sun Pharmaceutical Industries Ltd.
UCB S.A.
Viatris Inc.
Biogen

図表

LIST OF TABLES

TABLE 01. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 02. NEURODEGENERATIVE DRUGS MARKET FOR DOPAMINE AGONIST , BY REGION, 2021-2031 ($MILLION)
TABLE 03. NEURODEGENERATIVE DRUGS MARKET FOR DECARBOXYLASE INHIBITORS , BY REGION, 2021-2031 ($MILLION)
TABLE 04. NEURODEGENERATIVE DRUGS MARKET FOR CHOLINESTERASE INHIBITORS , BY REGION, 2021-2031 ($MILLION)
TABLE 05. NEURODEGENERATIVE DRUGS MARKET FOR IMMUNOMODULATORS, BY REGION, 2021-2031 ($MILLION)
TABLE 06. NEURODEGENERATIVE DRUGS MARKET FOR OTHERS , BY REGION, 2021-2031 ($MILLION)
TABLE 07. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 08. NEURODEGENERATIVE DRUGS MARKET FOR PARKINSON'S DISEASE, BY REGION, 2021-2031 ($MILLION)
TABLE 09. NEURODEGENERATIVE DRUGS MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2021-2031 ($MILLION)
TABLE 10. NEURODEGENERATIVE DRUGS MARKET FOR MULTIPLE SCLEROSIS , BY REGION, 2021-2031 ($MILLION)
TABLE 11. NEURODEGENERATIVE DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 13. NEURODEGENERATIVE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 14. NEURODEGENERATIVE DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 15. NEURODEGENERATIVE DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 16. NEURODEGENERATIVE DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 17. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 18. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 19. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 20. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. U.S. NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 22. U.S. NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 23. U.S. NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 24. CANADA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 25. CANADA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 26. CANADA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 27. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 28. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 29. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 30. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 31. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 32. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 33. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 34. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 35. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 36. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 37. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 38. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 39. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 40. UK NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 41. UK NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 42. UK NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 43. ITALY NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 44. ITALY NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 45. ITALY NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 46. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 47. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 48. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 49. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 50. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 51. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 52. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 53. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 54. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 55. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 56. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 57. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 58. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 59. CHINA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 60. CHINA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 61. CHINA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 62. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 63. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 64. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 65. INDIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 66. INDIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 67. INDIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 68. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 69. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 70. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 74. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 75. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 76. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 77. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 78. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 79. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 80. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 81. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 82. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 83. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 84. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 85. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 86. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 87. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 88. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 89. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 90. NOVARTIS AG: KEY EXECUTIVES
TABLE 91. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 92. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 93. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 94. NOVARTIS AG: KEY STRATERGIES
TABLE 95. ABBVIE INC.: KEY EXECUTIVES
TABLE 96. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 97. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 98. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 99. ABBVIE INC.: KEY STRATERGIES
TABLE 100. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 101. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 102. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 103. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 106. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 107. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 108. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 109. SANOFI: KEY EXECUTIVES
TABLE 110. SANOFI: COMPANY SNAPSHOT
TABLE 111. SANOFI: PRODUCT SEGMENTS
TABLE 112. SANOFI: PRODUCT PORTFOLIO
TABLE 113. ORION CORPORATION: KEY EXECUTIVES
TABLE 114. ORION CORPORATION: COMPANY SNAPSHOT
TABLE 115. ORION CORPORATION: PRODUCT SEGMENTS
TABLE 116. ORION CORPORATION: PRODUCT PORTFOLIO
TABLE 117. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 118. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 121. UCB S.A.: KEY EXECUTIVES
TABLE 122. UCB S.A.: COMPANY SNAPSHOT
TABLE 123. UCB S.A.: PRODUCT SEGMENTS
TABLE 124. UCB S.A.: PRODUCT PORTFOLIO
TABLE 125. UCB S.A.: KEY STRATERGIES
TABLE 126. VIATRIS INC.: KEY EXECUTIVES
TABLE 127. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 128. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 129. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 130. BIOGEN: KEY EXECUTIVES
TABLE 131. BIOGEN: COMPANY SNAPSHOT
TABLE 132. BIOGEN: PRODUCT SEGMENTS
TABLE 133. BIOGEN: PRODUCT PORTFOLIO
TABLE 134. BIOGEN: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. NEURODEGENERATIVE DRUGS MARKET, 2021-2031
FIGURE 02. SEGMENTATION OF NEURODEGENERATIVE DRUGS MARKET, 2021-2031
FIGURE 03. TOP INVESTMENT POCKETS IN NEURODEGENERATIVE DRUGS MARKET (2022-2031)
FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALNEURODEGENERATIVE DRUGS MARKET
FIGURE 10. NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR DOPAMINE AGONIST , BY COUNTRY 2021 AND 2031(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR DECARBOXYLASE INHIBITORS , BY COUNTRY 2021 AND 2031(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR CHOLINESTERASE INHIBITORS , BY COUNTRY 2021 AND 2031(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR IMMUNOMODULATORS, BY COUNTRY 2021 AND 2031(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR OTHERS , BY COUNTRY 2021 AND 2031(%)
FIGURE 16. NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR PARKINSON'S DISEASE, BY COUNTRY 2021 AND 2031(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR ALZHEIMER'S DISEASE, BY COUNTRY 2021 AND 2031(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR MULTIPLE SCLEROSIS , BY COUNTRY 2021 AND 2031(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
FIGURE 21. NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021 AND 2031(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
FIGURE 25. NEURODEGENERATIVE DRUGS MARKET BY REGION, 2021
FIGURE 26. U.S. NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 27. CANADA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 28. MEXICO NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 29. GERMANY NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 30. FRANCE NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 31. UK NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 32. ITALY NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 33. SPAIN NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 34. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 35. JAPAN NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 36. CHINA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 37. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 38. INDIA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 39. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 40. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 41. BRAZIL NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 42. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 43. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 44. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 49. COMPETITIVE DASHBOARD
FIGURE 50. COMPETITIVE HEATMAP: NEURODEGENERATIVE DRUGS MARKET
FIGURE 51. TOP PLAYER POSITIONING, 2021
FIGURE 52. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 53. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 54. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 55. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 56. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 57. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 58. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 59. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 60. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 63. SANOFI: NET SALES, 2020-2022 ($MILLION)
FIGURE 64. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 65. SANOFI: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 66. ORION CORPORATION: NET SALES, 2020-2022 ($MILLION)
FIGURE 67. ORION CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 68. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 69. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 70. UCB S.A.: NET SALES, 2020-2022 ($MILLION)
FIGURE 71. UCB S.A.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 72. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 73. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 74. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 75. BIOGEN: REVENUE SHARE BY REGION, 2021 (%)

Product Code: A13213

The neurodegenerative drugs market valued for $36,277.20 million in 2021 and is estimated to reach $74,809.38 million by 2031, exhibiting a CAGR of 7.5% from 2022 to 2031. Neurodegenerative diseases refer to a group of disorders that primarily affect the neurons (nerve cells) in the brain and spinal cord, leading to their gradual degeneration. These diseases are usually progressive and chronic, and their symptoms worsen over time. Examples of neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). These conditions have a significant impact on a person's cognitive, motor, & sensory functions, and can ultimately lead to disability and death.

Drugs used to treat neurodegenerative diseases are medications that are designed to slow down the progression of the disease and/or relieve symptoms. The specific drugs used will depend on the type of neurodegenerative disease being treated. For example, drugs used to treat Alzheimer's disease include cholinesterase inhibitors and memantine, while drugs used to treat Parkinson's disease include levodopa, dopamine agonists, and MAO-B inhibitors.

The major factor that drives the growth of the global neurodegenerative drugs market is rise in demand for advanced drug types for controlling symptoms associated with neurodegenerative diseases. In addition, a strong pipeline for neurodegenerative disease is a key trend in the market, which is expected to fuel the growth of the market. Significant surge in patient population has led to increase in demand for drugs. However, complications associated with drug development process and side effects of drugs are expected to hamper the market growth.

On the other hand, high growth potential in untapped emerging countries, increase in pipeline products such as BAF312 & Orelabrutinib for treating multiple sclerosis disease, and continuous drug approval of neurodegenerative diseases are anticipated to provide lucrative opportunities to the market players. For instance, in January 2020, Novartis AG announced that the European Commission (EC) has approved Mayzent (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.

The neurodegenerative drugs market is segmented into drug class, indication, distribution channel, and region. By drug class, the market is categorized into dopamine agonists, decarboxylase inhibitors, cholinesterase inhibitors, immunomodulators, and others. By indication, the market is segregated into Parkinson's disease, Alzheimer's disease, multiple sclerosis, and others. By distribution channel, the market is classified into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global neurodegenerative drugs market are: AbbVie Inc., Biogen, F. Hoffmann-La Roche Ltd., Novartis AG, Orion Corporation, Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and UCB S.A. Key players operating in the market have adopted product approval, acquisition, collaboration, and agreement as their key strategies to expand their corporate training market share.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the neurodegenerative drugs market analysis from 2021 to 2031 to identify the prevailing neurodegenerative drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the neurodegenerative drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global neurodegenerative drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

Dopamine agonist
Decarboxylase inhibitors
Cholinesterase Inhibitors
Immunomodulators
Others

By Indication

Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Others

By Distribution Channel

Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Orion Corporation
Biogen
Sanofi
Viatris Inc.
Novartis AG
UCB S.A.
AbbVie Inc.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in prevalence of neurodegenerative diseases
  - 3.4.1.2. Initiatives by government and non-government organizations
  - 3.4.1.3. Expected launch of new drugs during the forecast period

3.4.2. Restraints
- 3.4.2.1. Complications associated with drug development

3.4.3. Opportunities
- 3.4.3.1. Increase in R&D activities

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Dopamine agonist
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Decarboxylase inhibitors
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Cholinesterase Inhibitors
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Immunomodulators
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Others
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country

CHAPTER 5: NEURODEGENERATIVE DRUGS MARKET, BY INDICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Parkinson's Disease
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Alzheimer's Disease
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Multiple Sclerosis
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Others
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country

CHAPTER 6: NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Online Providers
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Drug Stores and Retail Pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: NEURODEGENERATIVE DRUGS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Drug Class
- 7.2.3. Market size and forecast, by Indication
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Drug Class
  - 7.2.5.1.3. Market size and forecast, by Indication
  - 7.2.5.1.4. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Drug Class
  - 7.2.5.2.3. Market size and forecast, by Indication
  - 7.2.5.2.4. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Drug Class
  - 7.2.5.3.3. Market size and forecast, by Indication
  - 7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Drug Class
- 7.3.3. Market size and forecast, by Indication
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Drug Class
  - 7.3.5.1.3. Market size and forecast, by Indication
  - 7.3.5.1.4. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Drug Class
  - 7.3.5.2.3. Market size and forecast, by Indication
  - 7.3.5.2.4. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Drug Class
  - 7.3.5.3.3. Market size and forecast, by Indication
  - 7.3.5.3.4. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Drug Class
  - 7.3.5.4.3. Market size and forecast, by Indication
  - 7.3.5.4.4. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Drug Class
  - 7.3.5.5.3. Market size and forecast, by Indication
  - 7.3.5.5.4. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Drug Class
  - 7.3.5.6.3. Market size and forecast, by Indication
  - 7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Drug Class
- 7.4.3. Market size and forecast, by Indication
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Drug Class
  - 7.4.5.1.3. Market size and forecast, by Indication
  - 7.4.5.1.4. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Drug Class
  - 7.4.5.2.3. Market size and forecast, by Indication
  - 7.4.5.2.4. Market size and forecast, by Distribution Channel
  - 7.4.5.3. Australia
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Drug Class
  - 7.4.5.3.3. Market size and forecast, by Indication
  - 7.4.5.3.4. Market size and forecast, by Distribution Channel
  - 7.4.5.4. India
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Drug Class
  - 7.4.5.4.3. Market size and forecast, by Indication
  - 7.4.5.4.4. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Drug Class
  - 7.4.5.5.3. Market size and forecast, by Indication
  - 7.4.5.5.4. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Drug Class
  - 7.4.5.6.3. Market size and forecast, by Indication
  - 7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Drug Class
- 7.5.3. Market size and forecast, by Indication
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Drug Class
  - 7.5.5.1.3. Market size and forecast, by Indication
  - 7.5.5.1.4. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Drug Class
  - 7.5.5.2.3. Market size and forecast, by Indication
  - 7.5.5.2.4. Market size and forecast, by Distribution Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Drug Class
  - 7.5.5.3.3. Market size and forecast, by Indication
  - 7.5.5.3.4. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Drug Class
  - 7.5.5.4.3. Market size and forecast, by Indication
  - 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

9.1. Novartis AG
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. AbbVie Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. F. Hoffmann-La Roche Ltd.
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Teva Pharmaceutical Industries Ltd.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Sanofi
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. Orion Corporation
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. Sun Pharmaceutical Industries Ltd.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. UCB S.A.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. Viatris Inc.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Biogen
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments

神経変性薬市場：薬剤クラス別、適応症別、流通チャネル別：2021-2031年の世界機会分析と産業予測

Neurodegenerative Drugs Market By Drug Class, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章神経変性薬市場：薬剤クラス別

第5章神経変性薬市場：適応症別

第6章神経変性薬市場：流通チャネル別

第7章神経変性薬市場：地域別

第8章競合情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Drug Class

By Indication

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS

CHAPTER 5: NEURODEGENERATIVE DRUGS MARKET, BY INDICATION

CHAPTER 6: NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: NEURODEGENERATIVE DRUGS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

神経変性薬市場：薬剤クラス別、適応症別、流通チャネル別：2021-2031年の世界機会分析と産業予測

Neurodegenerative Drugs Market By Drug Class, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 神経変性薬市場：薬剤クラス別

第5章 神経変性薬市場：適応症別

第6章 神経変性薬市場：流通チャネル別

第7章 神経変性薬市場：地域別

第8章 競合情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Drug Class

By Indication

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS

CHAPTER 5: NEURODEGENERATIVE DRUGS MARKET, BY INDICATION

CHAPTER 6: NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: NEURODEGENERATIVE DRUGS MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章神経変性薬市場：薬剤クラス別

第5章神経変性薬市場：適応症別

第6章神経変性薬市場：流通チャネル別

第7章神経変性薬市場：地域別

第8章競合情勢

第9章企業プロファイル